BACKGROUND AND OBJECTIVES: Proteinuria is used as an indicator of FSGS disease activity, but its use as a clinical trial end point is not universally accepted. The goal of this study was to refine proteinuria definitions associated with long-term kidney survival. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data on 466 patients with primary FSGS with proteinuria (urine protein-to-creatinine ratio >1 g/g) were analyzed from five independent cohorts. Proteinuria by months 1, 4, and 8 after study baseline was categorized by conventional definitions of complete (<0.3 g/g) and partial remission (<3.5 g/g and 50% reduction in proteinuria). Novel remission definitions were explored using receiver operating curves. Kaplan-Meier methods were used to estimate the associations of proteinuria with progression to ESRD or a 50% loss in kidney function. Propensity score-adjusted Cox proportional hazards models were used to adjust for baseline proteinuria, eGFR, and therapy. RESULTS: In the initial derivation cohort, conventional partial remission was not associated with kidney survival. A novel definition of partial remission (40% proteinuria reduction and proteinuria<1.5 g/g) on the basis of receiver operating curve analyses of 89 patients was identified (Sensitivity=0.70; Specificity=0.77). In the validation cohort analyses, complete remission was associated with better prognosis (6 out of 41 patients progressed to kidney failure; 6.6 per 100 patient-years) as was the novel partial remission (13 out of 71 progressed; 8.5 per 100 patient-years), compared with those with no response (51 out of 116 progressed; 20.1 per 100 patient-years). Conventional partial remission at month 8, but not month 4, was also associated with better response (19 out of 85 patients progressed; risk=10.4 per 100 patient-years). Propensity score-adjusted analyses showed the novel partial remission was associated with less progression at months 4 and 8 (month 4: hazard ratio, 0.50; P=0.01; month 8: hazard ratio, 0.30; P=0.002). CONCLUSIONS: Reaching either a complete or partial remission using a novel or conventional definition was associated with better long-term outcomes in patients with FSGS. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_02_20_CJASNPodcast_18_3_T.mp3.
BACKGROUND AND OBJECTIVES:Proteinuria is used as an indicator of FSGS disease activity, but its use as a clinical trial end point is not universally accepted. The goal of this study was to refine proteinuria definitions associated with long-term kidney survival. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data on 466 patients with primary FSGS with proteinuria (urine protein-to-creatinine ratio >1 g/g) were analyzed from five independent cohorts. Proteinuria by months 1, 4, and 8 after study baseline was categorized by conventional definitions of complete (<0.3 g/g) and partial remission (<3.5 g/g and 50% reduction in proteinuria). Novel remission definitions were explored using receiver operating curves. Kaplan-Meier methods were used to estimate the associations of proteinuria with progression to ESRD or a 50% loss in kidney function. Propensity score-adjusted Cox proportional hazards models were used to adjust for baseline proteinuria, eGFR, and therapy. RESULTS: In the initial derivation cohort, conventional partial remission was not associated with kidney survival. A novel definition of partial remission (40% proteinuria reduction and proteinuria<1.5 g/g) on the basis of receiver operating curve analyses of 89 patients was identified (Sensitivity=0.70; Specificity=0.77). In the validation cohort analyses, complete remission was associated with better prognosis (6 out of 41 patients progressed to kidney failure; 6.6 per 100 patient-years) as was the novel partial remission (13 out of 71 progressed; 8.5 per 100 patient-years), compared with those with no response (51 out of 116 progressed; 20.1 per 100 patient-years). Conventional partial remission at month 8, but not month 4, was also associated with better response (19 out of 85 patients progressed; risk=10.4 per 100 patient-years). Propensity score-adjusted analyses showed the novel partial remission was associated with less progression at months 4 and 8 (month 4: hazard ratio, 0.50; P=0.01; month 8: hazard ratio, 0.30; P=0.002). CONCLUSIONS: Reaching either a complete or partial remission using a novel or conventional definition was associated with better long-term outcomes in patients with FSGS. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_02_20_CJASNPodcast_18_3_T.mp3.
Authors: Debbie S Gipson; Hyunsook Chin; Trevor P Presler; Caroline Jennette; Maria E Ferris; Susan Massengill; Keisha Gibson; David B Thomas Journal: Pediatr Nephrol Date: 2006-01-05 Impact factor: 3.714
Authors: Stéphan Troyanov; Catherine A Wall; Judith A Miller; James W Scholey; Daniel C Cattran Journal: J Am Soc Nephrol Date: 2005-02-16 Impact factor: 10.121
Authors: Laura H Mariani; Sebastian Martini; Laura Barisoni; Pietro A Canetta; Jonathan P Troost; Jeffrey B Hodgin; Matthew Palmer; Avi Z Rosenberg; Kevin V Lemley; Hui-Ping Chien; Jarcy Zee; Abigail Smith; Gerald B Appel; Howard Trachtman; Stephen M Hewitt; Matthias Kretzler; Serena M Bagnasco Journal: Nephrol Dial Transplant Date: 2018-02-01 Impact factor: 5.992
Authors: Andrew S Levey; Daniel Cattran; Aaron Friedman; W Greg Miller; John Sedor; Katherine Tuttle; Bertram Kasiske; Thomas Hostetter Journal: Am J Kidney Dis Date: 2009-07-03 Impact factor: 8.860
Authors: Lesley A Inker; Hasi Mondal; Tom Greene; Taylor Masaschi; Francesco Locatelli; Francesco P Schena; Ritsuko Katafuchi; Gerald B Appel; Bart D Maes; Philip K Li; Manuel Praga; Lucia Del Vecchio; Simeone Andrulli; Carlo Manno; Eduardo Gutierrez; Alex Mercer; Kevin J Carroll; Christopher H Schmid; Andrew S Levey Journal: Am J Kidney Dis Date: 2016-03-29 Impact factor: 8.860
Authors: Crystal A Gadegbeku; Debbie S Gipson; Lawrence B Holzman; Akinlolu O Ojo; Peter X K Song; Laura Barisoni; Matthew G Sampson; Jeffrey B Kopp; Kevin V Lemley; Peter J Nelson; Chrysta C Lienczewski; Sharon G Adler; Gerald B Appel; Daniel C Cattran; Michael J Choi; Gabriel Contreras; Katherine M Dell; Fernando C Fervenza; Keisha L Gibson; Larry A Greenbaum; Joel D Hernandez; Stephen M Hewitt; Sangeeta R Hingorani; Michelle Hladunewich; Marie C Hogan; Susan L Hogan; Frederick J Kaskel; John C Lieske; Kevin E C Meyers; Patrick H Nachman; Cynthia C Nast; Alicia M Neu; Heather N Reich; John R Sedor; Christine B Sethna; Howard Trachtman; Katherine R Tuttle; Olga Zhdanova; Gastòn E Zilleruelo; Matthias Kretzler Journal: Kidney Int Date: 2013-01-16 Impact factor: 10.612
Authors: Debbie S Gipson; Michelle A Hladunewich; Richard Lafayette; John R Sedor; Brad H Rovin; Sean J Barbour; Alan McMahon; J Charles Jennette; Patrick H Nachman; Robert N Willette; Marcella Paglione; Feng Gao; Jorge Alfonso Ross Terres; Sue Vallow; M Claire Holland; Kevin S Thorneloe; Dennis L Sprecher Journal: Kidney Int Rep Date: 2020-05-26
Authors: Howard Trachtman; Peter Nelson; Sharon Adler; Kirk N Campbell; Abanti Chaudhuri; Vimal Kumar Derebail; Giovanni Gambaro; Loreto Gesualdo; Debbie S Gipson; Jonathan Hogan; Kenneth Lieberman; Brad Marder; Kevin Edward Meyers; Esmat Mustafa; Jai Radhakrishnan; Tarak Srivastava; Miganush Stepanians; Vladimír Tesar; Olga Zhdanova; Radko Komers Journal: J Am Soc Nephrol Date: 2018-11 Impact factor: 10.121
Authors: Debbie S Gipson; Howard Trachtman; Anne Waldo; Keisha L Gibson; Sean Eddy; Katherine M Dell; Tarak Srivastava; Kevin V Lemley; Larry A Greenbaum; Sangeeta Hingorani; Kevin E Meyers; Frederick J Kaskel; Kimberly J Reidy; Christine B Sethna; Cheryl L Tran; Chia-Shi Wang; Katherine R Tuttle; Gia Oh; Alicia M Neu; Elizabeth Brown; Jen-Jar Lin; Jennifer Lai Yee; Therese M Roth; Jonathan P Troost; Brenda W Gillespie; Matthew G Sampson; Matthias Kretzler; Wenjun Ju Journal: Kidney Int Rep Date: 2019-12-05
Authors: Yan-Cheng Chao; Howard Trachtman; Debbie S Gipson; Cathie Spino; Thomas M Braun; Kelley M Kidwell Journal: Contemp Clin Trials Date: 2020-03-19 Impact factor: 2.226
Authors: Jonathan P Troost; Howard Trachtman; Cathie Spino; Frederick J Kaskel; Aaron Friedman; Marva M Moxey-Mims; Richard N Fine; Jennifer J Gassman; Jeffrey B Kopp; Liron Walsh; Rong Wang; Debbie S Gipson Journal: Am J Kidney Dis Date: 2020-08-10 Impact factor: 8.860